Lantern Pharma Inc.
Clinical trials sponsored by Lantern Pharma Inc., explained in plain language.
AI-driven oncology drug development company.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New hope for never-smokers with advanced lung cancer: experimental drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests whether adding the experimental drug LP-300 to standard chemotherapy can help people who have never smoked and have advanced lung cancer that has returned after targeted therapy. About 90 participants will receive either the drug combo or chemo alone. The goal is…
Phase: PHASE2 • Sponsor: Lantern Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for tough cancers: experimental drug LP-284 enters human testing
Disease control Recruiting nowThis early-stage study tests a new drug called LP-284 in about 110 adults whose lymphomas or solid tumors have returned or stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug move…
Phase: PHASE1 • Sponsor: Lantern Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC